SAN DIEGO, Jan. 30, 2015 -- TRACON Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 3,600,000 shares of common stock at a price to the public of $10.00 per share.
TRACON Pharmaceuticals (OTC:TCON) said it is discontinuing development of its oncology drug candidate envafolimab after a key clinical trial failed to meet its primary endpoint and will concentrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results